ClinicalTrials.gg
CompletedNCT01928459Updated Dec 9, 2020

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

A Phase 1 interventional study of BGJ398 and BYL719 in Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
13th of 38
62 · median 44
Started
2013
with 2 others
Phase 1
14 of 38
1 open now
Registered
8th of 38
by date
Lead sponsor
18 of 38
Novartis Pharmaceuticals

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 3 that started in 2013, is one of 14 in phase 1, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

Read the detailed description

This dose escalation/dose expansion study will evaluate the combination of orally administered BGJ398 in combination with orally administered BYL719. During the dose escalation part, the MTD of the combination will be determined in patients whose advanced or metastatic tumors express mutations to PIK3CA. Once the MTD has been determined, the expansion part will begin. Patients will be addd to one of three arms based on the disease type and genetic changes. Patients with metastatic colorectal cancer are not eligible for participation in the expansion part.

03

Conditions studied

  • Advanced Solid Tumors
  • Metastatic Solid Tumors

Keywords

  • BGJ398
  • BYL719
  • advanced solid tumor
  • metastatic breast cancer
  • PK3CA
  • FGFR
  • fibroblast growth factor receptor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed advanced or solid tumors who have failed standard therapy or for whom no effective standard anti-cancer therapy exists
  • Documented PIK3CA mutations in all patients in dose escalation and expansion with or without documented genetic alterations in FGFR depending upon dose expansion cohort (either local or central determination)
  • defined by v1.1
  • performance status of ≤2

Exclusion criteria

Exclusion Criteria:

  • Prior PI3Ki or selective FGFR inhibitor treatment (for patients enrolled to expansion part)
  • Colorectal cancer (for patients enrolled to expansion part)
  • Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L, history of gestational diabetes mellitus or documented -induced diabetes mellitus
  • Use of medications that increase serum levels of phosphorus and/or calcium
  • Inorganic phosphorus outside of normal limits
  • Total and ionized serum calcium outside of normal limits
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Metastatic breast cancer

    Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.

    Drug: BGJ398 · Drug: BYL719

  • Experimental
    Solid tumor arm 1

    Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.

    Drug: BGJ398 · Drug: BYL719

  • Experimental
    Solid tumor arm 2

    Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3

    Drug: BGJ398 · Drug: BYL719

  • Experimental
    Dose escalation

    To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.

    Drug: BGJ398 · Drug: BYL719

Interventions

  • DrugBGJ398

    BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

  • DrugBYL719

    BYL719 will be administered orally once daily on each day of the 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719

    The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.

    Time frame: Approximately 8 months

Secondary outcomes

  1. Safety and tolerability of BGJ398/BYL719 combination at the recommended dose for expansion (RDE)

    This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions

    Time frame: Every 28 days from baseline visit until end of study visit

  2. Overall response rate

    Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719; Overall response rate = complete response + partial response

    Time frame: Every two months from the date of baseline CT scan

  3. Progression free survival

    Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719

    Time frame: Every two months from the date of baseline CT scan

  4. Time vs. concentration profile of BGJ398 and BYL719

    Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of the combination of BGJ398 with BYL719

    Time frame: Every 28 days for up to 10 cycles

07

Study locations

22 sites
  • H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
    Tampa, Florida 33612, United States
  • University of Michigan Comprehensive Cancer Center SC
    Ann Arbor, Michigan 48109-0944, United States
  • Karmanos Cancer Institute Dept of Onc
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine Onc Dept
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center Onc Dept
    New York, New York 10065, United States
  • Vanderbilt University Medical Center Dept of Onc
    Nashville, Tennessee 37232, United States
  • Cancer Therapy & Research Center / UT Health Science Center SC
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Lyon Cedex, 69373, France
  • Novartis Investigative Site
    Saint Herblain cedex, 44805, France
  • Novartis Investigative Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • Novartis Investigative Site
    Milano, MI 20141, Italy
  • Novartis Investigative Site
    Modena, MO 41100, Italy
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, 1066 CX, Netherlands
  • Novartis Investigative Site
    Singapore, 169610, Singapore
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28050, Spain
  • Novartis Investigative Site
    Bellinzona, 6500, Switzerland
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2013
First posted
Aug 26, 2013
Start
Oct 2013
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01928459
Responsible party
Sponsor
First posted
Aug 26, 2013
Start date
Oct 2013
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Dec 9, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infigratinib · Alpelisib

Start the discussion